Advertisement

PharmacoEconomics

, Volume 37, Issue 10, pp 1301–1302 | Cite as

Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’

  • Livio GarattiniEmail author
  • Anna Padula
Letter to the Editor

Notes

Compliance with Ethical Standards

Funding

No sources of funding were received for the preparation of this commentary.

Conflict of interest

Livio Garattini and Anna Padula have no conflicts of interest that are directly relevant to the content of this commentary.

References

  1. 1.
    Leal J, Manetti S, Buchanan J. The impact of hospital costing methods on cost-effectiveness analysis: a case study. Pharmacoeconomics. 2018;36(10):1263–72.CrossRefGoogle Scholar
  2. 2.
    Garattini L, Padula A. Dutch guidelines for economic evaluation: ‘from good to better’ in theory but further away from pharmaceuticals in practice? J R Soc Med. 2017;110(3):98–103.CrossRefGoogle Scholar
  3. 3.
    Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 1987.Google Scholar
  4. 4.
    Garattini L, Curto A, Padula A, Freemantle N. Real-world evidence in economic evaluations: really realistic? J R Soc Med. 2016;109(11):404–7.CrossRefGoogle Scholar
  5. 5.
    Garattini L, Grilli R, Scopelliti D, Mantovani L. A proposal for Italian guidelines in pharmacoeconomics. Pharmacoeconomics. 1995;7(1):1–6.CrossRefGoogle Scholar
  6. 6.
    Garattini L, Padula A. Pharmaceutical pricing conundrum: time to get rid of it? Eur J Health Econ. 2018;19(8):1035–8.CrossRefGoogle Scholar
  7. 7.
    Garattini L, Curto A, Freemantle N. Pharmaceutical price schemes in Europe: time for a ‘continental’ one? Pharmacoeconomics. 2016;34(5):423–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.CESAV, Centre for Health Economics, “Mario Negri” Institute for Pharmacological Research (IRCCS)RanicaItaly

Personalised recommendations